Trial Profile
deLIVER: Direct Acting Antiviral Effects on the Liver
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary) ; Sofosbuvir/velpatasvir/voxilaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms deLIVER
- 30 Dec 2020 Status changed from active, no longer recruiting to completed.
- 03 Jun 2020 Planned End Date changed from 1 May 2020 to 1 Dec 2020.
- 15 Jan 2020 Planned End Date changed from 1 Jan 2020 to 1 May 2020.